Summary
A company in Taiwan is working on a new treatment for solid tumors using a modified cell therapy called CAR001. This approach aims to overcome challenges that current therapies face, especially those that are effective in blood cancers but not in solid tumors.
Key Facts
- CAR-T therapy has been successful in treating blood cancers but struggles with solid tumors.
- Solid tumors make up more than 90% of all cancer cases worldwide.
- CAR001 is a new type of CAR-T therapy specially designed for solid tumors.
- CAR001 uses γδ T-cells to recognize tumors without relying on traditional methods, making it more versatile for different patients.
- The therapy targets HLA-G, a molecule often found in advanced solid tumors, to improve immune system response.
- CAR001 also uses an anti–PD-L1 bispecific T-cell engager to help localize treatment within the tumor.
- This development comes from a collaboration with Ever Supreme BioTechnology, based in Taiwan.
